Investing.com - Crispr Therapeutics (NASDAQ: CRSP) reported first quarter EPS of $-1.43, $0.08 worse than the analyst estimate of $-1.35. Revenue for the quarter came in at $504K versus the consensus estimate of $25.53M.
Crispr Therapeutics's stock price closed at $53.29. It is down -23.88% in the last 3 months and down -21.37% in the last 12 months.
Crispr Therapeutics saw 10 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Crispr Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Crispr Therapeutics's Financial Health score is "good performance".
Check out Crispr Therapeutics's recent earnings performance, and Crispr Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar